孕激素受体分子影像纵向监测揭示活化ESR1突变乳腺癌内分泌治疗早期差异反应
研究利用表达野生型ER或活化ESR1突变Y537S-ER的T47D乳腺癌细胞构建小鼠移植瘤模型,比较基线18F-FES摄取及氟维司群治疗前后18F-FFNP和18F-FDG PET/CT变化。结果显示Y537S-ER肿瘤呈雌激素非依赖生长且对氟维司群仅稳定体积,基线18F-FES摄取无显著差异,早期代谢反应相似,但氟维司群治疗后野生型肿瘤18F-FFNP摄取显著降低而Y537S-ER肿瘤无显著变化。提示PR表达动态分子影像可无创早期识别活化ESR1突变所致内分泌治疗疗效降低。
要点
- 活化ESR1突变Y537S-ER移植瘤呈雌激素非依赖生长,氟维司群仅稳定肿瘤体积。
- 基线18F-FES摄取在野生型与Y537S-ER肿瘤间无显著差异。
- 氟维司群治疗后野生型肿瘤18F-FFNP摄取显著降低,Y537S-ER肿瘤无显著变化。
核心结论
- 孕激素受体表达动态分子影像有望无创早期识别活化ESR1突变导致的内分泌治疗疗效降低。
研究设计与样本
- 采用表达野生型ER或活化ESR1突变Y537S-ER的ER+、PR+ T47D乳腺癌细胞在卵巢切除免疫缺陷雌鼠中构建移植瘤模型。
- 比较基线18F-FES摄取,并在氟维司群治疗前及开始后7-9天进行18F-FFNP和18F-FDG纵向PET/CT显像。
主要发现
- Y537S-ER移植瘤呈雌激素非依赖生长,野生型ER肿瘤仅在雌激素存在时生长。
- 氟维司群治疗28天显著缩小野生型ER肿瘤体积,但对Y537S-ER肿瘤仅稳定体积。
- 基线18F-FES摄取在野生型ER与Y537S-ER肿瘤间无显著差异。
- 氟维司群治疗对野生型ER和Y537S-ER肿瘤诱导相似的早期代谢反应。
- 氟维司群治疗7天后野生型ER肿瘤18F-FFNP摄取显著降低,Y537S-ER肿瘤基线至随访PET/CT无显著变化。
临床怎么用
- PR表达动态分子影像或可用于早期识别活化ESR1突变乳腺癌患者内分泌治疗疗效降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activating mutations in the estrogen receptor (ER) α-gene (ESR1) result in constitutive transcriptional activity in the absence of estrogen and are associated with endocrine resistance in metastatic ER-positive (+) breast cancer. It is not known how activating ESR1 mutations may alter the predictive values of molecular imaging agents for endocrine therapy response. This study investigated the effect of an activating ESR1 mutation on pretreatment 18F-fluoroestradiol (18F-FES) uptake and early assessment of endocrine therapy response using 18F-FDG and 18F-fluorofuranylnorprogesterone (18F-FFNP) PET/CT imaging of tumor glucose metabolism and progesterone receptor (PR) expression, respectively. Methods: ER+, PR+ T47D breast cancer cells expressing wild-type (WT) ER or an activating ESR1 mutation, Y537S-ER, were used to generate tumor xenografts in ovariectomized female immunodeficient mice supplemented with 17β-estradiol. Tumor growth curves were determined in the presence or absence of estrogen and for ethanol vehicle control or fulvestrant treatment, a selective ER degrader. Pretreatment 18F-FES uptake was compared between Y537S-ER and WT-ER tumors. Longitudinal PET/CT imaging with 18F-FFNP and 18F-FDG was performed before and 7-9 d after the start of endocrine therapy with fulvestrant. Radiopharmaceutical uptake in Y537S-ER and WT-ER tumors was compared between baseline and follow-up scans. Statistical significance was determined using paired t testing for longitudinal imaging and 2-way ANOVA for the 18F-FFNP tissue biodistribution assay. Results: Y537S-ER xenografts showed estrogen-independent growth, whereas WT-ER tumors grew only with estrogen. Fulvestrant treatment for 28 d significantly reduced tumor volumes for WT-ER but only stabilized volumes for Y537S-ER. Baseline 18F-FES uptake did not significantly differ between WT-ER and Y537S-ER tumors. Fulvestrant treatment induced a similar early metabolic response for both WT-ER and Y537S-ER tumors. 18F-FFNP uptake in WT-ER tumors was significantly reduced after 7 d of fulvestrant treatment; however, this reduction did not occur in Y537S-ER tumors, which showed no significant change between baseline and follow-up PET/CT. Conclusion: Molecular imaging of PR expression dynamics could be a noninvasive approach for early identification of reduced effectiveness of endocrine therapy resulting from activating ESR1 mutations.
引用
- Kumar M, Salem K, Jeffery JJ, et al. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation. J Nucl Med. 2020. PMID: 32859700. doi:10.2967/jnumed.120.249508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。